The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer

Human Pathology

Volumn 27, Issue 9, 1996, Pages 955-963

  O'Malley, Frances P ^a   Saad, Zahida ^b   Kerkvliet, Nancy ^b   Doig, Gordon ^b   Stitt, Larry ^b   Ainsworth, Peter ^b   Hundal, Harsh ^b   Chambers, Ann F ^b   Turnbull, D Ian ^b   Bramwell, Vivien ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

breast cancer; c erb B 2; lymph node negative; p53; prognosis

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CARCINOMA IN SITU; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE C ERB; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 16044373760     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90224-5     Document Type: Article

References (54)

1. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study. N Engl J Med 320:485-490, 1989
2. McGuire WL: Adjuvant therapy of node-negative breast cancer. N Engl J Med 320:525-527, 1989
3. Page DL: Prognosis and breast cancer: Recognition of lethal and favorable prognostic types. Am J Surg Pathol 15:334-349, 1991
4. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992
5. McGuire WL, Tandon AK, Allred DC, et al: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990
6. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30:117-126, 1994
7. Lane DP, Crawford LV: T-antigen is bound to host protein in SV40 transformed cells. Nature 278:261-263, 1979
8. Vogelstein B: A deadly inheritance. Nature 348:681-682, 1990
9. Malkin D, Li FP, Strong LC: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
10. Marx J: Genetic defect identified in rare cancer syndrome: A mutation in the p53 tumor suppressor gene underlies the high cancer rate in members of Li-Fraumeni families. Science 250:1209, 1990
11. Cattoretti G, Rilke F, Andreola S, et al: p53 Expression in breast cancer. Int J Cancer 41:178-183, 1988
12. Gamel JW, Meyer JS, Province MA: Proliferative rate by S-phase measurement may affect cure of breast carcinoma. Cancer 76:1009-1018, 1995
13. Davidoff AM, Humphrey PA, Iglehart JD, et al: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 88:5006-5010, 1991
14. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
15. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-854, 1992
16. Silvestrini R, Benini E, Daidone MG, et al: p53 As an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
17. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the erbB-2/ neu oncogene. Science 235:177-182, 1987
18. Lovekin C, Ellis IO, Locker A, et al: c-erb-B2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
19. McCann A, Dervan PA, O'Regan M, et al: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Treat Res 51:3296-3303, 1991
20. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991
21. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in nodenegative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
22. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
23. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
24. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377, 1957
25. Holland R, Connolly JL, Gellman R, et al: The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 8:113-118, 1990
26. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741-748, 1991
27. Hsu SM, Raine L, Fanger H: The use of avidin-biotin peroxidase complex (ABC) and immunoperoxidase technique: A comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
28. Dubeau L, Chandler LA, Gralow JR, et al: Southern blot analysis of DNA extracted from formalin-fixed pathology specimens. Cancer Treat Res 46:2964-2969, 1986
29. Dubeau L, Weinberg K, Jones PA, et al: Studies on immunoglobin gene rearrangement in formalin-fixed, paraffin-embedded pathology specimens. Am J Pathol 130:588-594, 1988
30. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
31. Fisher B, Constantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
32. Fisher B, Redmond C, Nikolay V, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracilin in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:473-478, 1989
33. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
34. Davidoff AM, HerndonJE, Glover NS, et al: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110:259-264, 1991
35. Poller DN, Hutchings CE, Galea M: p53 protein expression in human breast carcinoma: Relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and estrogen receptor. Br J Cancer 66:583-588, 1992
36. Trudel M, Mulligan L, Cavenee W: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. HUM PATHOL 23:1388-1394, 1992
37. Ostrowski JL, Sawan A, Henry L, et al: p53 Expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 164:75-81, 1991
38. Chang K, Ding I, Kern FG: Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. J Histochem Cytochem 39:1281-1287, 1991
39. Barnes DM, Dubin EA, Fisher CJ: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? HUM PATHOL 24:469-476, 1993
40. Charpin C, JacquemierJ, Andrac L: Multiparameter analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in non malignant and malignant breast disorders. Am J Pathol 132:199-211, 1988
41. Sklarew RJ, Bodmer SC, Pertschuk LP: Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry 11:359-378, 1990
42. McClelland RA, Finlay P, Walker KJ: Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Treat Res 50:3545-3550, 1990
43. Elledge RM, Clark GM, Fuqua SA, et al: p53 protein accumulation detected by five different antibodies: Relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54:3752-3757, 1994
44. Ravdin PM, Tandon AK, Allred DC, et al: Cathepsin D by Western blotting and immunohistochemistry: Failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12:467-474, 1994
45. Coles C, Condie A, Chetty U, et al: p53 Mutations in breast cancer. Cancer Treat Res 52:5291, 1992
46. Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, et al: Specific interaction between the p53 cellular tumor antigen and major heat shock proteins. Nature 320:182-184, 1986
47. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
48. Hurlimann P, Chaubert P, Benhatttar J: p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: Correlation between immunohistochemical and molecular biology techniques. Mod Pathol 7:423-428, 1994
49. Dunn JM, Hastrich DJ, Newcomb P, et al: Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg 80:1410-1412, 1993
50. Thompson AM, Anderson TJ, Condie A, et al: p53 Allele losses, mutations, and expression in breast cancer and their relationship to clinico-pathological parameters. IntJ Cancer 50:528-532, 1992
51. Lohmann D, Rubri C, Schmitt M, et al: Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer: Occurrence of false-positives and false-negatives. Diagn Mol Pathol 2:36-41, 1993
52. VarleyJM, Brammar WJ, Lane DP, et al: Loss of chromosome 17 p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413-421, 1991
53. Ravdin PM, Clark GM, Hilsenbeck SG, et al: A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat 21:47-53, 1992
54. McGuire WL, Tandon AK, Allred DC, et al: Treatment decisions in axillary node-negative breast cancer patients. Monogr Natl Cancer Inst 11:173-180, 1992